- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Shivam Tyagi
Latest Articles By Shivam Tyagi
Torrent Pharma Posts Net Profit Of Rs 287 Cr, Sales Up By 17% In Q4FY23
Ahmedabad-based Indian pharmaceutical major Torrent Pharmaceutical on Tuesday posted its financials for the fourth quarter and full year ending March 31, 2023. The company posted a net profit of Rs 287 crores in the January-March quarter against a net loss of Rs 188 crores recorded in Q4 last year
Read More
Fortis Healthcare Q4FY23 PAT Surges By 58.9% To Rs 138 Cr
Fortis Healthcare one of India's leading healthcare providers on Tuesday announced its audited consolidated financial results for the quarter and year ended 31 March 2023. The healthcare company has registered consolidated revenues of Rs1,643 crores, up by 19.2 per cent YoY in Q4FY23 against Rs 1,378 recorded in Q4FY22
Read More
Biocon's Net Profits Soar In Q4FY23 By 31% YoY, Revenues Up By 58.6%
Bangalore-based pharmaceutical company Biocon on Tuesday announced its consolidated financial results for the fourth quarter that ended 31st March 2023, the company registered a 58.6 per cent rise in its consolidated revenues from operations year on year. The company's consolidated revenue for the March quarter stood at Rs 3,928 crores against Rs 2,476 crores in the same quarter last year
Read More
Divi's Labs PAT Slumps By 64.2% In Q4FY23
Divi's Laboratories on Saturday announced its earnings for the fourth quarter and full year FY23. The company posted a drop in its net profits by 64.2 per cent year on year (YoY) in the March quarter to Rs 320 crores down from 894 crores in the same quarter of the previous year
Read More
Artificial Sweeteners: Experts Weigh In On Regulation, Reducing Dependence
The fate of non-sugar sweeteners (NSS) or popularly known as sugar-free substitutes might just be changing as the scientific evidence gathering against them suggests that the artificial sweeteners may not be efficacious for many health benefits that they were previously lauded for or which led to their fame
Read More
Gland Pharma's Net Profits Tank By 72.2% YoY In Q4FY23
Gland Pharma on Thursday announced its earnings for the fourth quarter and full year FY23. The company's revenue recorded a slump in Q4FY23 by 29.4 per cent year on year (YoY) to be recorded at Rs 824 crore and by 16.6 per cent for FY23 to Rs 3,856 crore compared with Rs 1,168 crore in Q4FY22 and Rs 4,624 in FY22 respectively
Read More
Max Healthcare's PAT Nearly Doubles In Q4FY23, Records Revenue At Rs 1,637 Cr
Max Healthcare, the Indian healthcare provider headquartered in New Delhi has reported its earnings for the quarter that ended on 31st March 2023, the hospital chain has registered a rise of 26 per cent year on year in its consolidated revenue to be recorded at Rs 1,637 crores in the Quarter Four of Financial Year 2023(Q4FY23) up from Rs 1,296 crores in the corresponding quarter last year
Read More
We Must Bring Down Some Cost Of Healthcare But Pay Workers What They Deserve: Dr Sangita Reddy
On the rising medical inflation in India which reports say is approximately at 14 per cent presently and is also the highest in Southeast Asia, Dr Sangita Reddy, Joint MD, Apollo Hospitals said while defending the Indian healthcare costs that the high-quality healthcare in India is available at one-tenth or one-sixth of the global prices and its prices are not high in many areas
Read More
Q4 Results: Cipla's Net Profit Rises By 40% YoY, Consolidated Revenue At 5,739 Cr
Cipla Limited, the Indian pharmaceutical major headquartered in Mumbai has reported its earnings for the quarter that ended on 31st March 2023, the Indian pharma giant has registered a rise of 8.3 per cent in its consolidated revenue to be recorded at Rs 5,739 crores in the Quarter Four of Financial Year 2022(Q4FY23) up from Rs 5,260 crores in the corresponding quarter last year
Read More
Govt’s New Medical Device Policy & How Will It Impact Industry: All You Need To Know
The six strategies of the National Medical Device Policy 2023, propose to augment the growth story of the medical devices industry in India and entail focus areas such as streamlining regulation, enabling infrastructure, facilitating R&D and innovation, inviting investments, facilitating skilled manpower and promoting the industry for exports
Read More
.jpg)
